Cortechs.ai and deepc Partner to Bring AI-Powered Radiology Tools into Clinical Workflows

Published Date: June 11, 2025

By News Release

On June 4, 2025, Cortechs.ai—a leader in AI-based medical imaging—announced a strategic alliance with deepc, the team behind the vendor-neutral radiology AI platform deepcOS®. This collaboration integrates Cortechs.ai’s key products—NeuroQuant®, NeuroQuant® MS, NeuroQuant® Brain Tumor, and OnQ™ Prostate—directly into the deepcOS® system for the first time.

Broadening Global Access to Validated AI Tools
Cortechs.ai’s AI solutions, already recognized for their clinical efficacy in the U.S., have been assigned Category III CPT codes for quantitative brain MRI. This designation reflects both clinical trust and readiness for broader adoption and reimbursement. The integration with deepcOS® expands availability beyond Cortechs.ai’s in‑house platform, offering hospitals worldwide—including in Europe—access to these proven tools.

Streamlined Deployment for Clinicians
By embedding Cortechs.ai’s portfolio into deepcOS®, health systems can effortlessly deploy AI-enhanced imaging tools directly within their workflows. These tools cover:

NeuroQuant® & NeuroQuant® MS – Fully automated brain segmentation and volume analysis to detect and monitor neurodegenerative diseases like Alzheimer’s and multiple sclerosis.
NeuroQuant® Brain Tumor – Quantitative assessment of tumor size and progression.
OnQ™ Prostate – Improved analysis of prostate MRI for cancer detection.

These are now available via deepcOS®, offering fast implementation with regulatory compliance and clinical validation packed into one scalable platform.

A Shared Mission for Scalable, Secure AI
The partnership emphasizes the shared goal of enhancing radiology workflows, reducing diagnostic challenges, and supporting personalized care through interoperable and secure AI solutions.
Kyle Frye, CEO of Cortechs.ai, describes the deal as a major move to deliver trusted AI insights globally. Dr. Franz Pfister, CEO and Co-founder of deepc, echoed this, noting the collaboration aligns with deepc’s goal of deploying clinically impactful, reimbursable AI at scale.